We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP
Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations. He has worked in various B2B and B2C environments, including in leadership roles at Roland Berger, KaDeWe Group, Camp David, Grundig, and Thomas Cook. Most recently, he joins us from QE-3 Equity Partners.
At ROTOP, Dr. Peterseim will be responsible for Finance/Controlling, HR, and IT/Technology and will support the next phase of our growth, with a particular focus on process optimization and new construction investments.
Ähnliche Beiträge
New CFO at ROTOP – Dr. Michael Peterseim
March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.
ROTOP Pharmaka Welcomes State Minister Dirk Panter: Radiopharmacy as a Key Technology in Modern Cancer Care
January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.
ROTOP featured in VentureCapital Magazine
August 15, 2025 - We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions.
